Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 135 for:    Pancreatic Cancer | ( Map: South Korea )

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03572400
Recruitment Status : Recruiting
First Posted : June 28, 2018
Last Update Posted : September 27, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Do-Youn Oh, Seoul National University Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 30, 2021
Estimated Study Completion Date : November 30, 2021